0000000000117184

AUTHOR

Thomas Wehler

showing 30 related works from this author

Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoprolif…

2010

Long term immunosuppression and therapy of acute rejections result in a 20-120-fold increased risk to develop Non Hodgkin lymphoma (NHL). Since immunosuppressive therapy and immunological disorders are major risk factors for the development of NHL in the non-transplant population we aimed to analyze risk factors for PTLD in our cohort of liver transplanted (LT) patients.We analyzed retrospectively 431 patients liver transplanted between 1998 and 2008.PTLD was diagnosed in eleven of 431 patients (2.6%). PTLD, especially late PTLD, was significantly more frequent in patients who received steroids before LT (Kaplan-Meier: p0.001). Moreover PTLD in immunocompromised patients with preoperative s…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPopulationAutoimmune hepatitisKaplan-Meier EstimateLiver transplantationGastroenterologyYoung AdultPostoperative ComplicationsRisk Factorshemic and lymphatic diseasesInternal medicinePreoperative CareInternal MedicinemedicineCadaverHumansProspective cohort studyeducationChildAgedProportional Hazards ModelsRetrospective StudiesHepatitiseducation.field_of_studybusiness.industryLymphoma Non-HodgkinRetrospective cohort studyImmunosuppressionMiddle Agedmedicine.diseaseTissue DonorsLymphomaLiver TransplantationHepatitis Autoimmunesurgical procedures operativeImmunologyMultivariate AnalysisFemaleSteroidsbusinessImmunosuppressive AgentsEuropean journal of internal medicine
researchProduct

Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung…

2016

Abstract Background: Preclinical studies demonstrated that local radiotherapy (RT) acts synergistically with RNActive mRNA vaccines to enhance anti-tumor effects and increase tumor-infiltrating lymphocytes. BI 1361849 is a therapeutic vaccine comprising optimized mRNA constituents encoding six NSCLC-associated antigens. Interim data of a phase Ib study, employing local RT to increase the immune mediated tumor control by BI 1361849, have been previously published (J Clin Oncol 34, 2016, suppl; abstr e20627). Here we report results of immune response analyses as well as updated safety and efficacy data. Methods: Patients (pts) with stage IV NSCLC were enrolled in three cohorts based on histol…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybiologybusiness.industrymedicine.medical_treatmentImmunogenicityImmunologyCancermedicine.diseasePemetrexedImmune systemCancer immunotherapyInternal medicineImmunologymedicinebiology.proteinCancer vaccineEpidermal growth factor receptorbusinessmedicine.drugCancer Immunology Research
researchProduct

Cylindromatosis (Cyld) gene mutation in T cells promotes the development of an IL-9-dependent allergic phenotype in experimental asthma

2016

Cylindromatosis (CYLD) is a ubiquitously expressed deubiquitinating enzyme which removes activating ubiquitin residues from important signaling molecules of the NF-κB pathway. In CYLDex7/8 transgenic mice, a naturally occurring short isoform (sCYLD) is overexpressed in the absence of full length CYLD, leading to excessive NF-κB activity. Herein, we investigated the impact of the CYLDex7/8 mutation selectively in T cells on the development of experimental allergic airway disease induced by sensitization and challenge with ovalbumin. Compared with their wildtype littermates, mice bearing the T cell-specific mutation (CD4+CYLDex7/8) display stronger eosinophilia and mucus production in the lun…

CD4-Positive T-Lymphocytes0301 basic medicineSkin Neoplasmsmedicine.medical_treatmentT cellImmunologyGene mutationImmunoglobulin Emedicine.disease_causeTh9 cellsDeubiquitinating enzymeMice03 medical and health sciencesNeoplastic Syndromes HereditaryHypersensitivitymedicineAnimalsHumansSensitizationMice KnockoutMutationbiologyTumor Suppressor ProteinsInterleukin-9Cylindromatosis (turban tumor syndrome) geneIL-9AsthmaDeubiquitinating Enzyme CYLDEosinophilsMice Inbred C57BLMucusOvalbumin030104 developmental biologymedicine.anatomical_structureCytokineModels AnimalMutationImmunologybiology.proteinCellular Immunology
researchProduct

Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell–depleted reduced-intensity transplantation

2006

AbstractAllogeneic hematopoietic stem cell transplantation (SCT) regimens incorporating the lymphocytotoxic CD52 antibody alemtuzumab demonstrate efficient engraftment and reduced graft-versus-host disease (GVHD). However, these protocols substantially impair posttransplantation antiviral and antitumor immunity. To accelerate immune reconstitution after alemtuzumab-based reduced-intensity SCT, we administered prophylactic CD8-depleted donor lymphocyte infusions (DLIs) starting on days 60 and 120 after transplantation. DLIs were processed in an immunomagnetic good manufacturing practice depletion procedure resulting in a 2.5- to 6-log reduction in CD8 T cells. Of 23 high-risk patients with h…

AdultMaleTransplantation ConditioningCD52Antibodies Neoplasmmedicine.medical_treatmentT cellImmunologyGraft vs Host DiseaseHematopoietic stem cell transplantationCD8-Positive T-LymphocytesAntibodies Monoclonal HumanizedImmunotherapy AdoptiveBiochemistryLymphocyte DepletionHLA AntigensmedicineHumansCytotoxic T cellAlemtuzumabPeripheral Blood Stem Cell TransplantationImmunomagnetic Separationbusiness.industryGraft SurvivalAntibodies MonoclonalCell BiologyHematologyMiddle AgedDonor Lymphocytesmedicine.diseaseTransplantationTreatment Outcomesurgical procedures operativeGraft-versus-host diseasemedicine.anatomical_structureHematologic NeoplasmsLangerhans CellsImmunologyAlemtuzumabFemaleK562 CellsbusinessFollow-Up Studiesmedicine.drugBlood
researchProduct

Strong Expression of Chemokine Receptor CXCR4 by Renal Cell Carcinoma Correlates with Advanced Disease

2008

Diverse chemokines and their receptors have been associated with tumor growth, tumor dissemination, and local immune escape. In different tumor entities, the level of chemokine receptorCXCR4 expression has been linked with tumor progression and decreased survival. The aim of this study was to evaluate the influence ofCXCR4 expression on the progression of human renal cell carcinoma.CXCR4 expression of renal cell carcinoma was assessed by immunohistochemistry in 113 patients. Intensity ofCXCR4 expression was correlated with both tumor and patient characteristics. Human renal cell carcinoma revealed variable intensities ofCXCR4 expression. StrongCXCR4 expression of renal cell carcinoma was si…

Pathologymedicine.medical_specialtyChemokineArticle Subjectbiologybusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCXCR4lcsh:RC254-282Chemokine receptorOncologyTumor progressionRenal cell carcinomaAdvanced diseasebiology.proteinMedicineImmunohistochemistrybusinessReceptorResearch ArticleJournal of Oncology
researchProduct

29: Rapid expansion of acute myeloid leukemia-reactive cytotoxic T cells from CD8+CD62L+ blood lymphocytes of HLA-matched healthy donors in vitro

2007

Transplantationbusiness.industryRapid expansionCancer researchMyeloid leukemiaMedicineCytotoxic T cellHematologyHuman leukocyte antigenbusinessCD8In vitroBiology of Blood and Marrow Transplantation
researchProduct

297: Establishment of a chimeric NOD-scid/IL2RγcNull transplantation-model to evaluate graft-vs-host and graft-vs-leukemia immune responses of ex viv…

2007

musculoskeletal diseasesTransplantationbusiness.industryHost (biology)NodT lymphocyteHematologymedicine.diseaseVirologyTransplantationstomatognathic diseasesLeukemiaImmune systemimmune system diseaseshemic and lymphatic diseasesImmunologyMedicinebusinessEx vivoBiology of Blood and Marrow Transplantation
researchProduct

Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.

2019

The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea.Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses wer…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtyLung NeoplasmsCross-sectional studyPopulation03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungSurveys and QuestionnairesMedicineHumansSurvivorsLung cancereducationAgedAged 80 and overeducation.field_of_studybusiness.industryCancerMiddle Agedmedicine.diseasePrognosisCombined Modality TherapyhumanitiesSurvival Rate030104 developmental biologyCross-Sectional StudiesOncologyMulticenter study030220 oncology & carcinogenesisQuality of LifePatient-reported outcomeFemaleActive treatmentbusinessFollow-Up StudiesJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
researchProduct

Erratum to: Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation. Methods The study presented was a retrospective analysis of 50 gastrointestinal cancer patients treated with cetuximab in combination with either FOLFIRI or FOLFOX. One cohort of 15 patients received an in-house reactive skin protocol upon development of an exanthema. A second cohort of 15 patients received a skin prophylaxis starting with the first dose of cetuximab before clinical signs of toxicity. A third historic group o…

MaleCancer ResearchColorectal cancerAdministration TopicalAdministration OralCetuximabMinocyclineGastroenterologyPeritoneal NeoplasmPeritoneal NeoplasmsGastrointestinal NeoplasmsSkinHematologyintegumentary systemCetuximabTherapy reactiveMultimodal therapyVitamin K 1General MedicineMiddle AgedCombined Modality TherapyAnti-Bacterial AgentsSurvival RateTreatment OutcomeAppendiceal NeoplasmsOncologyColonic NeoplasmsAdenocarcinomaFemaleErratumQuinolizinesFluoroquinolonesmedicine.drugmedicine.medical_specialtyPrednisoloneEGFRDetergentsAntineoplastic AgentsAdenocarcinomaAntibodies Monoclonal HumanizedDisease-Free SurvivalMetronidazoleRashInternal medicineIntestinal NeoplasmsmedicineCombined Modality TherapyHumansSurvival rateAgedRetrospective StudiesOriginal PaperRectal Neoplasmsbusiness.industryRetrospective cohort studyAntibiotic ProphylaxisExanthemamedicine.diseaseDermatologydigestive system diseasesSurgerybusinessJournal of Cancer Research and Clinical Oncology
researchProduct

Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues

2016

C-X-C motif chemokine ligand 12 (CXCL12), also termed stromal cell-derived factor-1 (SDF-1) is a small protein 8-14 kDa in length that is expressed as six isoforms, consisting of SDF-1α, SDF-1β, SDF-1γ, SDF-1δ, SDF-1ε and SDF-1θ. All six isoforms are encoded by the single CXCL12 gene on chromosome 10. This gene regulates leukocyte trafficking and is variably expressed in a number of normal and cancer tissues. The potential role of the novel CXCL12 splice variants as components of the CXCR4 axis in cancer development is not fully understood. The present study aimed to analyze the expression profile of the various SDF-1 isoforms and SDF-1 polymorphisms, and the association with the clinicopat…

0301 basic medicineGene isoformCancer ResearchPathologymedicine.medical_specialtyOncogeneArticlesBiologymedicine.diseasePrimary tumorCXCR403 medical and health sciences030104 developmental biology0302 clinical medicineOncologyTumor progression030220 oncology & carcinogenesisGenotypemedicineCancer researchGene polymorphismTumor markerOncology Letters
researchProduct

Rapid identification of minor histocompatibility antigen HA-1 subtypes H and R using fluorescence-labeled oligonucleotides

2000

Acknowledgments: We thank Brigitte Schuch and Karola Schmidt for excellent technical assistance. This work was supported by a grant of the Deutsche Krebshilfe (Nr. 70-2427 and Nr. 70-2428). Abstract: Donor-recipient disparitiy of the minor histocompatibility antigen HA-1 is relevant for the development of graft-versus-host disease after HLA-matched sibling allogeneic bone marrow transplantation in HLA-A*0201-positive individuals. Two different alleles of HA-1 with a single amino acid polymorphism have been identified. Here we describe a time- and cost-efficient method for HA-1 typing of genomic DNA, using site-specific hybridization probes with the LightCycler. This method was compared with…

Allogeneic transplantationOligonucleotideImmunologyGeneral MedicineBiologyBiochemistryFluorescenceMolecular biologylaw.inventiongenomic DNAlawGeneticsMinor histocompatibility antigenImmunology and AllergyTypingAllelePolymerase chain reactionTissue Antigens
researchProduct

Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents

2016

Undifferentiated pleomorphic sarcoma not otherwise specified belongs to the heterogeneous group of soft tissue tumors. It is preferentially located in the upper and lower extremities of the body, and surgical resection remains the only curative treatment. Preclinical animal models are crucial to improve the development of novel chemotherapeutic agents for the treatment of undifferentiated pleomorphic sarcoma. However, this approach has been hampered by the lack of reproducible animal models. The present study established two xenograft animal models generated from stable non-clonal cell cultures, and investigated the difference in chemotherapeutic effects on tumor growth between undifferenti…

0301 basic medicineCancer ResearchPathologymedicine.medical_specialtymedicine.drug_classHistone deacetylase inhibitorArticlesCell cycleBiologyUndifferentiated Pleomorphic SarcomaTyrosine-kinase inhibitorPazopanib03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyIn vivo030220 oncology & carcinogenesismedicineDoxorubicinVorinostatmedicine.drugOncology Letters
researchProduct

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?

2007

AIM: To define the (co-)expression pattern of target receptor-tyrosine-kinases (RTK) in human gastric adenocarcinoma. METHODS: The (co-)expression pattern of VEGFR1-3, PDGFRα/β and EGFR1 was analyzed by RT-PCR in 51 human gastric adenocarcinomas. In addition, IHC staining was applied for confirmation of expression and analysis of RTK localisation. RESULTS: The majority of samples revealed a VEGFR1 (98%), VEGFR2 (80%), VEGFR3 (67%), PDGFRα (82%) and PDGFRβ (82%) expression, whereas only 62% exhibited an EGFR1 expression. 78% of cancers expressed at least four out of six RTKs. While VEGFR1-3 and PDGFRα revealed a predominantly cytoplasmatic staining in tumor cells, accompanied by an additiona…

Pathologymedicine.medical_specialtyStromal cellAntineoplastic AgentsAdenocarcinomaReceptor tyrosine kinaseStomach NeoplasmsmedicineGastric mucosaHumansProtein Kinase InhibitorsbiologyReverse Transcriptase Polymerase Chain ReactionfungiGastroenterologyReceptor Protein-Tyrosine KinasesCancerGeneral Medicinemedicine.diseaseImmunohistochemistrydigestive system diseasesStainingmedicine.anatomical_structureGastric MucosaDrug Designbiology.proteinCancer researchAdenocarcinomaImmunohistochemistryDrug Therapy CombinationRapid CommunicationPlatelet-derived growth factor receptorWorld Journal of Gastroenterology
researchProduct

Structure-Based Discovery of Small Molecules Binding to RNA

2017

Ribonucleic acids (RNAs) constitute attractive drug targets. The wealth of structural information about RNAs is steadily increasing making it possible to use this information for the design of new ligands. Two methods that make heavy use of structural knowledge for ligand discovery are molecular docking and fragment screening. In molecular docking the structure of the binding site is used as a template for the design of new ligands using computational methods whereas in fragment screening biophysical methods are used for the detection of weak binding ligands which are subsequently elaborated into tighter binding molecules. In this chapter, we give an overview of both methods in the context …

0301 basic medicineRiboswitch010405 organic chemistryChemistryLigandBinding proteinRNAComputational biology01 natural sciencesSmall molecule0104 chemical sciences03 medical and health sciences030104 developmental biologyDocking (molecular)Structure basedBinding site
researchProduct

Rapid Expansion of Acute Myeloid Leukemia-Reactive Cytotoxic T Cells from CD8+CD62L+ Blood Lymphocytes of HLA-Matched Healthy Donors In Vitro

2006

Abstract Allogeneic cytotoxic T-lymphocyte (CTL) therapy in acute myeloid leukemia (AML) is hampered by the poor efficiency of growing leukemia-reactive CTLs from healthy donors in vitro. We established an allogeneic mini-mixed lymphocyte-leukemia culture (MLLC) approach by stimulating comparably small numbers (104/well) of CD8+ T cells isolated from healthy donors against irradiated primary AML blasts in 96-well plates. Prior to use, CD8+ T cells were immunomagnetically separated into a CD62L(high)+ subset enriched for naive precursors and central memory cells as well as a CD62L(low)+/negative subset containing effector memory cells. The culture medium contained IL-7, IL-12, and IL-15. Aft…

ELISPOTImmunologyMyeloid leukemiaCell BiologyHematologyHuman leukocyte antigenBiologyBiochemistryHaematopoiesisCTL*Antigenhemic and lymphatic diseasesImmunologyCytotoxic T cellCD8Blood
researchProduct

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4

2006

In different tumour entities, expression of the chemokine receptor 4 (CXCR4) has been linked to tumour dissemination and poor prognosis. Therefore, we evaluated, if the expression of CXCR4 exerts similar effects in human hepatocellular carcinoma (HCC). Expression analysis and functional assays were performed in vitro to elucidate the impact of CXCL12 on human hepatoma cells lines. In addition, expression of CXCR4 was evaluated in 39 patients with HCC semiquantitatively and correlated with both, tumour and patients characteristics. Human HCC and hepatoma cell lines displayed variable intensities of CXCR4 expression. Loss of p53 function did not impact on CXCR4 expression. Exposure to CXCL12 …

MaleReceptors CXCR4Cancer ResearchChemokinePathologymedicine.medical_specialtyCarcinoma HepatocellularActive Transport Cell NucleusliverSensitivity and SpecificityCXCR4MetastasisChemokine receptorhepatocellularCell MovementPredictive Value of TestsTumor Cells CulturedCarcinomamedicinemetastasisHumansNeoplasm InvasivenessReceptorMolecular DiagnosticsCell ProliferationCXCR4biologychemokineLiver NeoplasmsMiddle AgedFlow Cytometrymedicine.diseaseImmunohistochemistryChemokine CXCL12digestive system diseasesSurvival RateOncologyHepatocellular carcinomaDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleChemokines CXCBritish Journal of Cancer
researchProduct

Campath-1H-Based Reduced-Intensity Conditioning Followed by Allogeneic Blood Stem-Cell Transplantation and Preemptive CD8-Depleted Donor Lymphocyte I…

2004

Abstract Recent reports have demonstrated the feasibility of using the anti-CD52 antibody Campath-1H for in vivo T-cell depletion (TCD) in the context of a fludarabine/melphalan-based reduced-intensity conditioning regimen (Kottaridis et al. Blood 2000, 96:2419). Major disadvantage of this protocol is the severe immunosuppression which results in an increased rate of opportunistic infections and disease relapses. Donor lymphocyte infusions (DLI) are frequently used to overcome this limitation. The application of DLI, however, is associated with a profound risk of GvHD. Depletion of CD8+ lymphocytes from either the allotransplant or from DLI has proven feasible to reduce the incidence of GvH…

Melphalanbusiness.industrymedicine.medical_treatmentLymphocyteImmunologyImmunosuppressionCell BiologyHematologymedicine.diseaseBiochemistryFludarabineTransplantationmedicine.anatomical_structureGraft-versus-host diseaseImmunologyMedicinebusinessPreparative Regimenmedicine.drugAllotransplantationBlood
researchProduct

Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML…

2008

Objective Current in vitro techniques for isolating leukemia-reactive cytotoxic T lymphocytes (CTLs) from healthy donors are of relatively low efficiency and yield responder populations with unknown biological significance. This study aimed at the development of a more reliable approach, allowing generation and expansion of acute myeloid leukemia (AML)-reactive CTLs using primary in vitro stimulation. Materials and Methods We established allogeneic mini-mixed lymphocyte-leukemia cultures (mini-MLLCs) by stimulating donor CD8 + T cells with human leukocyte antigen (HLA) class I–matched AML blasts in microtiter plates. Before culture, CD8 + T cells were separated into CD62L (high)+ and CD62L …

Cancer ResearchMyeloidGenes MHC Class Ichemical and pharmacologic phenomenaHuman leukocyte antigenMice SCIDBiologyCD8-Positive T-LymphocytesMiceImmune systemMice Inbred NODhemic and lymphatic diseasesGeneticsmedicineCytotoxic T cellAnimalsHumansL-SelectinMolecular BiologyAllelesCells CulturedMice KnockoutMyeloid leukemiahemic and immune systemsCell BiologyHematologyReference Standardsmedicine.diseaseCytotoxicity Tests ImmunologicClone CellsCTL*LeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureImmunologyCD8Neoplasm TransplantationInterleukin Receptor Common gamma SubunitT-Lymphocytes CytotoxicExperimental hematology
researchProduct

Characterization of Renal-Cell Carcinoma (RCC)-Reactive Cytotoxic T-Lymphocyte Responses Generated from Peripheral Blood of HLA-Matched Sibling and U…

2004

Abstract Although current allo-transplantation therapy can induce considerable graft-versus-tumor (GvT) effects in RCC patients, it is also accompanied by severe, even life-threatening side effects, mainly due to graft-versus-host disease (GvHD). Efforts aiming to improve the specificity and efficiency of allogeneic cell therapy in this disease (e.g. specific donor lymphocyte infusion or vaccination) will certainly benefit from the identification of potential anti-tumor effector mechanisms and their corresponding target structures. We recently demonstrated that RCC-reactive cytotoxic T-lymphocyte (CTL) clones can be isolated from peripheral blood of healthy donors matched with the RCC stimu…

LymphocyteImmunologyCell BiologyHematologyHuman leukocyte antigenBiologyBiochemistryPeripheral blood mononuclear cellTransplantationCTL*medicine.anatomical_structureAntigenImmunologymedicineCytotoxic T cellCD8Blood
researchProduct

Rapid identification and sorting of viable virus-reactive CD4+ and CD8+ T cells based on antigen-triggered CD137 expression

2008

Abstract Current methods for the detection and isolation of antigen-specific CD4 + and CD8 + T cells require the availability of peptide/MHC multimers or are restricted to cells that produce cytokines after antigen contact. Here we show that de novo cell surface expression of the TNF-receptor family member CD137 (4-1BB) identifies recently activated, but not resting, human CD4 + and CD8 + memory T cells. Maximum CD137 expression level is uniformly observed in both T-cell subsets at 24h after stimulation with antigen. In experiments with CMV and EBV-reactive T cells, we confirmed the specificity of CD137 expression by co-staining with peptide/HLA tetramers. Substantial proportions of CD137 +…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanImmunologyCytomegalovirusStreptamerCD8-Positive T-LymphocytesLymphocyte ActivationViral Matrix ProteinsInterferon-gammaTumor Necrosis Factor Receptor Superfamily Member 9Interleukin 21HumansImmunology and AllergyCytotoxic T cellIL-2 receptorAntigen-presenting cellAntigens ViralCD40biologyImmunomagnetic SeparationCD28PhosphoproteinsNatural killer T cellAdoptive TransferMolecular biologyGene Expression Regulationbiology.proteinK562 CellsJournal of Immunological Methods
researchProduct

Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.

2006

AbstractAllogeneic cell therapy as a means to break immunotolerance to solid tumors is increasingly used for cancer treatment. To investigate cellular alloimmune responses in a human tumor model, primary cultures were established from renal cell carcinoma (RCC) tissues of 56 patients. In three patients with stable RCC line and human leukocyte antigen (HLA)-identical sibling donor available, allogeneic and autologous RCC reactivities were compared using mixed lymphocyte/tumor cell cultures (MLTC). Responding lymphocytes were exclusively CD8+ T cells, whereas CD4+ T cells or natural killer cells were never observed. Sibling MLTC populations showed higher proliferative and cytolytic antitumor …

Interleukin 2Cytotoxicity ImmunologicCancer ResearchCD3 ComplexCell SurvivalLymphocyteCD8 AntigensEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesLymphocytes Tumor-InfiltratingAntigenAntibody SpecificityHLA AntigensCell Line TumormedicineTumor Cells CulturedCytotoxic T cellHumansL-SelectinCarcinoma Renal CellCell ProliferationTumor-infiltrating lymphocytesSiblingsAntibodies MonoclonalFlow CytometryKidney NeoplasmsCTL*medicine.anatomical_structureOncologyImmunologyCD8medicine.drugT-Lymphocytes CytotoxicCancer research
researchProduct

Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer.

2006

Despite many pathophysiological analyses, the process of tumor dissemination of hepatocellular carcinoma (HCC) remains vague. In diverse tumor entities, expression of the chemokine receptor, CCR7, has been linked to tumor dissemination and poor prognosis. Therefore, we evaluated, whether CCR7 exerts similar effects in human HCC. CCR7 expression analysis was performed in vitro on human hepatoma cell lines (Huh7, Hep3B, wt HepG2, p53 dominant negative transfected HepG2). In addition, CCR7 expression was evaluated in 39 patients with hepatocellular cancer and correlated with both, tumor and patients characteristics. Human hepatocellular carcinoma samples and hepatoma cell lines displayed varia…

MaleCancer ResearchPathologymedicine.medical_specialtyReceptors CCR7Carcinoma Hepatocellularchemical and pharmacologic phenomenaC-C chemokine receptor type 7BiologyMetastasisChemokine receptorimmune system diseasesCell Line TumormedicineCarcinomaHumansGenetic Predisposition to DiseaseAgedGenes DominantOncogeneLiver NeoplasmsCancerhemic and immune systemsGeneral MedicineMiddle Agedmedicine.diseasePrognosisdigestive system diseasesGene Expression Regulation NeoplasticLymphatic systemOncologyLiverHepatocellular carcinomaLymphatic MetastasisFemaleReceptors ChemokineOncology reports
researchProduct

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

2013

Purpose Treatment with cetuximab is accompanied by the development of an acneiform follicular skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) develops in about 9–19 % of patients with the necessity of cetuximab dose reduction or cessation.

medicine.medical_specialtyCancer ResearchHematologyCetuximabintegumentary systembusiness.industryGeneral MedicineMinocyclineRashDermatologydigestive system diseasesSurgeryMetronidazoleOncologyInternal medicineMonoclonalmedicinePrednisolonemedicine.symptomAntibiotic prophylaxisbusinessneoplasmsmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

186: Superior antitumor in vitro responses of allogeneic matched sibling compared to autologous patient CD8+ T cells

2007

Allogeneic cell therapy as a means to break immunotolerance to solid tumors is increasingly used for cancer treatment. To investigate cellular alloimmune responses in a human tumor model, primary cultures were established from renal cell carcinoma (RCC) tissues of 56patients. In three patients with stable RCC line and human leukocyte antigen (HLA)-identical sibling donor available, allogeneic and autologous RCC reactivities were compared using mixed lymphocyte/ tumor cell cultures (MLTC). Responding lymphocytes were exclusively CD8 + T cells, whereas CD4 + T cells or natural killer cells were never observed. Sibling MLTC populations showed higher proliferative and cytolytic antitumor respon…

Transplantationbiologybusiness.industryCD3LymphocyteHuman leukocyte antigenHematologyCD16HaematopoiesisCTL*medicine.anatomical_structurebiology.proteinCancer researchMedicineCytotoxic T cellbusinessCD8Biology of Blood and Marrow Transplantation
researchProduct

Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.

2006

AbstractIn HLA-incompatible hematopoietic stem cell transplantation, alloreactive donor T cells recognizing recipient mismatch HLA cause severe graft-versus-host disease (GVHD). Strategies allowing the selective depletion of alloreactive T cells as well as the enhancement of graft-versus-malignancy immunity would be beneficial. We generated donor CD8 T-cell lines in vitro using allogeneic recipient cells mismatched at a single HLA class I allele or haplotype as stimulators. Recipient cells were obtained from acute myeloid leukemias, renal-cell carcinomas, and CD40L-induced B lymphoblasts. Resulting alloreactive T cells were activated by incubating day 21 T-cell cultures with HLA-mismatch tr…

CD4-Positive T-LymphocytesHerpesvirus 4 HumanIsoantigensT cellImmunologyCD40 LigandCytomegalovirusGraft vs Host DiseaseHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationTransfectionBiochemistryImmunotherapy AdoptiveLymphocyte DepletionTumor Necrosis Factor Receptor Superfamily Member 9AntigenHLA AntigensT-Lymphocyte SubsetsmedicineCytotoxic T cellHumansCarcinoma Renal CellCells CulturedSkinB-LymphocytesImmunomagnetic SeparationLymphoblastCD137Cell BiologyHematologyT lymphocyteFibroblastsCytotoxicity Tests ImmunologicKidney Neoplasmsmedicine.anatomical_structureLeukemia MyeloidHistocompatibilityImmunologyK562 CellsCD8Blood
researchProduct

Preemptive Transfer of GMP-Grade CD8-Depleted Donor Lymphocytes after T-Cell Depleted Reduced-Intensity Transplantation.

2005

Abstract The combination of fludarabin (150mg/m2) / melphalan (140mg/m2) based reduced-intensity allo-transplantation (RIT) with in vivo T-cell depletion (TCD) by the anti-CD52 antibody alemtuzumab (100mg) has demonstrated efficient engraftment and reduced graft-versus-host disease (GVHD) (Kottaridis et al., Blood 2000). However, the slow lymphocyte recovery following this protocol is associated with reduced anti-infectious and antitumor immunity. In an attempt to improve immune-reconstitution after TCD / RIT, we investigated the early preemptive use of CD8-depleted donor lymphocyte infusions (DLIs). For CD8 depletion of donor leukaphereses, a new depletion protocol using clinical grade CD8…

business.industryT cellLymphocyteImmunologyCell BiologyHematologyLeukapheresismedicine.diseaseDonor LymphocytesBiochemistryTransplantationAnimal datamedicine.anatomical_structureGraft-versus-host diseaseImmunologymedicineAlemtuzumabbusinessmedicine.drugBlood
researchProduct

PDGFRa/β expression correlates with the metastatic behavior of human colorectal cancer: A possible rationale for a molecular targeting strategy

2008

As new multi-target tyrosine kinase inhibitors are emerging in the therapy of various malignancies, our aim was to define the co-expression pattern of receptor-tyrosine-kinase platelet-derived growth factor receptors alpha and beta (PDGFRalpha/beta) in human colorectal cancer. The co-expression pattern of PDGFRalpha/beta was analyzed by RT-PCR in 99 histologically confirmed human colorectal carcinomas and five colorectal cancer cell lines. In addition, immunohistochemical (IHC) staining was applied for confirmation of expression and analysis of receptor tyrosine kinase (RTK) localisation. The colorectal cancer cell lines that were analysed revealed varying expression intensities of PDGFRalp…

Cancer ResearchPathologymedicine.medical_specialtyStromal cellbiologyOncogeneColorectal cancerbusiness.industryCancerGeneral Medicinemedicine.diseaseMolecular medicineOncologyGrowth factor receptorCancer researchbiology.proteinmedicineImmunohistochemistrybusinessPlatelet-derived growth factor receptor
researchProduct

Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.

2004

The design and successful clinical implementation of cancer vaccines targeting the induction of T-cell mediated immunity is a rapidly evolving field that is hampered by an empirical selection of antigen and adjuvant. In particular, vaccines using defined tumor-associated peptide epitopes elicit only a restricted T-cell repertoire in a minority of patients. In this regard, vaccines comprising the whole spectrum of antigens presented by individual autologous tumors would be advantageous. In an in vitro model, we evaluated the capacity of naturally processed Epstein-Barr virus-transformed B-lymphoblastoid-cell line (LCL)-derived peptides to activate virus-specific CD8+ T cells of seropositive …

AntigenicityHerpesvirus 4 HumanT cellImmunologyHuman leukocyte antigenBiologyCD8-Positive T-LymphocytesIn Vitro TechniquesLymphocyte ActivationCancer VaccinesEpitopeMonocytesEpitopesAntigenHLA AntigensmedicineImmunology and AllergyHumansProtease InhibitorsAntigen PresentationImmunogenicityHistocompatibility Antigens Class IDendritic cellDendritic CellsCell Transformation ViralMolecular biologyCell biologyClone Cellsmedicine.anatomical_structureProteasome inhibitorLymphocyte Culture Test MixedProteasome Inhibitorsmedicine.drugJournal of immunological methods
researchProduct

Psychological distress in lung cancer survivors at least 1 year after diagnosis-Results of a German multicenter cross-sectional study.

2017

AdultMaleLung NeoplasmsCross-sectional studyHealth StatusExperimental and Cognitive PsychologyAnxietyGerman03 medical and health sciences0302 clinical medicineCancer SurvivorsSurvivorship curveGermanySurveys and QuestionnairesmedicineHumans030212 general & internal medicineLung cancerDepression (differential diagnoses)Agedbusiness.industryDepressionPsychological distressMiddle Agedmedicine.diseaselanguage.human_languagePsychiatry and Mental healthDistressCross-Sectional StudiesOncology030220 oncology & carcinogenesislanguageAnxietyFemalemedicine.symptombusinessStress PsychologicalClinical psychologyPsycho-oncology
researchProduct

Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease

2006

Certain chemokines have been proposed to distinctly contribute to tumor growth, dissemination and local immune escape. Expression of the chemokine receptor CXCR4 has been linked to tumor progression in diverse tumor entities. The aim of this study was to evaluate if the expression of CXCR4 influences progression of human pancreatic cancer. CXCR4 expression of pancreatic cancer was retrospectively assessed by immunohistochemistry in 103 patients with pancreatic cancer. Intensity of CXCR4 expression was correlated with both tumor and patient characteristics. Human pancreatic cancer revealed variable intensities of CXCR4 expression. Strong CXCR4 expression was significantly associated with adv…

MaleCancer ResearchReceptors CXCR4Pancreatic diseaseBlotting WesternBiologyAdenocarcinomaMetastasisPancreatic cancermedicineBiomarkers TumorHumansAgedNeoplasm StagingRetrospective StudiesOncogeneCancerGeneral Medicinemedicine.diseaseImmunohistochemistryPancreatic Neoplasmsmedicine.anatomical_structureOncologyTumor progressionCancer researchCA19-9FemalePancreas
researchProduct